Literature DB >> 9636559

Steroid withdrawal in renal transplant recipients: pro point of view.

D E Hricik1.   

Abstract

Steroid-free immunosuppression remains an attractive goal in an era in which the transplant community should be promoting long-term allograft survival by reducing cardiovascular risk and maximizing long-term patient survival. In the cyclosporine era, the risks of steroid withdrawal outweighed the benefits of steroid withdrawal in a substantial minority of patients. A number of new immunosuppressants may prove to be more steroid sparing than cyclosporine alone and promise to increase the safety of steroid-free immunosuppression for renal transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9636559     DOI: 10.1016/s0041-1345(98)00282-6

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Prospective controlled protocol for three months steroid withdrawal with tacrolimus, basiliximab, and mycophenolate mofetil in renal transplant recipients.

Authors:  Chang-Kwon Oh; Su Jin Kim; Ji Hye Kim; Jong Hoon Lee
Journal:  J Korean Med Sci       Date:  2012-03-21       Impact factor: 2.153

2.  Tailored immunosuppression and steroid withdrawal in pancreas-kidney transplantation.

Authors:  Maura Rossetti; Giorgina B Piccoli; Manuel Burdese; Cesare Guarena; Roberta Giraudi; Elisabetta Mezza; Valentina Consiglio; Giorgio Soragna; Maria Messina; Giuseppe P Segoloni
Journal:  Rev Diabet Stud       Date:  2004-11-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.